Drug Profile
Research programme: hepatitis C virus therapeutics - Pfizer
Latest Information Update: 27 May 2021
Price :
$50
*
At a glance
- Originator Agouron Pharmaceuticals
- Developer Pfizer
- Class Gene therapies; Pyrones
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 01 Jan 2013 No development reported - Preclinical for Hepatitis C in USA (PO)
- 14 Sep 2010 Preclinical trials in Hepatitis C in USA (PO)
- 04 Aug 2009 No development reported - Preclinical for Hepatitis C in USA (PO)